{"nctId":"NCT00776230","briefTitle":"Immunogenicity of a Commercial Batch of JEV IC51 up to 24 Months Post Filling","startDateStruct":{"date":"2008-09"},"conditions":["Japanese Encephalitis"],"count":304,"armGroups":[{"label":"IC51 (~12 months post filling)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: IC51"]},{"label":"IC51 (~18 months post filling)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: IC51"]},{"label":"IC51 (~24 months post filling)","type":"ACTIVE_COMPARATOR","interventionNames":["Biological: IC51"]}],"interventions":[{"name":"IC51","otherNames":["Japanese Encephalitis vaccine"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male and female healthy adults aged at least 18 years with written informed consent and either no childbearing potential or negative pregnancy test.\n\nExclusion Criteria:\n\n* History of immunodeficiency or immunosuppressive therapy, known HIV infection, drug addiction including alcohol dependence, prior vaccination against JE","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Primary: 1. Geometric Mean Titers (GMT) at Day 56","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"100.1","spread":null},{"groupId":"OG001","value":"84.7","spread":null},{"groupId":"OG002","value":"68.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Secondary: 1. Seroconversion Rate 2. GMTs Day 28, Month 6 and Month 12 3. Treatment Emergent Adverse Events 4. Systemic and Local Tolerability","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":2,"n":98},"commonTop":["Headache","Influenza Like Illness","Fatigue","Nasopharyngitis","Myalgia"]}}}